Hippocratic AI expanded its life sciences footprint with the acquisition of Grove AI, adding agentic AI capabilities for pharmaceutical R&D and clinical trial operations to its existing patient-facing healthcare platform. Grove AI’s technology, including its AI agent “Grace,” supports participant engagement, recruitment, and follow-up across clinical trials and has powered more than 10 million patient interactions over the past year. The move is intended to reduce operational friction in highly regulated biopharma and medtech environments, where adoption of agentic AI has lagged due to stringent compliance and safety requirements.
Following the acquisition, Hippocratic AI established a dedicated life sciences division led by Ahad Wahid, a former NHS surgeon and longtime Boston Consulting Group partner, and formed a life sciences executive advisory council with senior leaders from major pharmaceutical, medtech, and research institutions. According to co-founder and CEO Munjal Shah, the strategy centers on building deeply specialized models with rigorous safety architectures that can operate across the full life sciences value chain, from clinical trials and patient support to commercial and provider engagement, while continuing to pursue additional acquisitions to accelerate growth in healthcare and life sciences.